Breaking News, Financial News

Financial Report: Biogen

Revenues up 7% in the quarter driven by TECFIDERA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen 1Q Revenues: $2.7 billion (+7%) 1Q Earnings: $971 million (+18%) Comments: Growth was driven by TECFIDERA sales, up 15% to $946 million. ELOCTATE sales were $108 million, up 101%, and ALPROLIX sales were $75 million, up 74%. Revenues were partially offset by a decrease in worldwide interferon sales, with AVONEX down 19%. TYSABRI sales were $477 million, up 3%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters